These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 39072179)
1. BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report. Sasaki M; Shimura T; Nishie H; Kuroyanagi K; Kanno T; Fukusada S; Sugimura N; Mizuno Y; Nukui T; Uno K; Kojima Y; Nishigaki R; Tanaka M; Ozeki K; Kubota E; Kataoka H World J Gastrointest Oncol; 2024 Jul; 16(7):3357-3363. PubMed ID: 39072179 [TBL] [Abstract][Full Text] [Related]
2. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Grothey A; Fakih M; Tabernero J Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264 [TBL] [Abstract][Full Text] [Related]
3. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748 [TBL] [Abstract][Full Text] [Related]
4. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. Kotani D; Bando H; Taniguchi H; Masuishi T; Komatsu Y; Yamaguchi K; Nakajima T; Satoh T; Nishina T; Esaki T; Nomura S; Takahashi K; Iida S; Matsuda S; Motonaga S; Fuse N; Sato A; Fujii S; Ohtsu A; Ebi H; Yoshino T ESMO Open; 2020; 5(1):e000624. PubMed ID: 33551068 [TBL] [Abstract][Full Text] [Related]
6. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847 [TBL] [Abstract][Full Text] [Related]
7. The BEETS (JACCRO CC-18) trial: an observational and translational study of Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. Li S; Hu H; Ding D; Zhu Y; Huang J Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738 [TBL] [Abstract][Full Text] [Related]
9. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. Kopetz S; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Belani A; Zhang X; Tabernero J ESMO Open; 2022 Jun; 7(3):100477. PubMed ID: 35653981 [TBL] [Abstract][Full Text] [Related]
11. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version]. Hummel M; Hegewisch-Becker S; Neumann J; Vogel A Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173 [TBL] [Abstract][Full Text] [Related]
12. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated Van Cutsem E; Taieb J; Yaeger R; Yoshino T; Grothey A; Maiello E; Elez E; Dekervel J; Ross P; Ruiz-Casado A; Graham J; Kato T; Ruffinelli JC; André T; Carrière Roussel E; Klauck I; Groc M; Vedovato JC; Tabernero J J Clin Oncol; 2023 May; 41(14):2628-2637. PubMed ID: 36763936 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study. Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039 [TBL] [Abstract][Full Text] [Related]
18. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403 [TBL] [Abstract][Full Text] [Related]
19. Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory Kawata A; Miyamoto Y; Fukubayashi K; Horio T; Miyamoto H; Ogawa K; Ouchi M; Tanaka Y; Baba H In Vivo; 2023; 37(4):1797-1801. PubMed ID: 37369457 [TBL] [Abstract][Full Text] [Related]